Back to discover

Protein / target

Low affinity immunoglobulin gamma Fc region receptor III-A

Encoded byFCGR3AP08637Homo sapiensSwiss-Prot
Clinical-stage
Therapeutic maturity
2
Clinical candidates
11
Clinical trials
Small-molecule tractable
Druggability
Structure with Ligand

Protein at a glance

Biological role

Low-affinity IgG receptor

Strongest disease association

Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity

Via encoding gene FCGR3A · Genetic literature evidence · score 0.82

Therapeutic position

Clinically advancing target

Antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG).

View complete UniProt function annotation

Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger (PubMed:11711607, PubMed:21768335, PubMed:22023369, PubMed:24412922, PubMed:25786175, PubMed:25816339, PubMed:28652325, PubMed:8609432, PubMed:9242542). Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC (PubMed:24412922, PubMed:25786175). Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis (PubMed:29967280, PubMed:9916693). Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation. The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation (PubMed:1825220, PubMed:23024279, PubMed:2532305). Costimulates NK cells and trigger lysis of target cells independently of IgG binding (PubMed:10318937, PubMed:23006327). Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells (PubMed:27670158). Mediates enhanced opsonization and ADCC in response to afucosylated IgGs (PubMed:34485821, PubMed:28566370)

Subcellular location

Cell membraneSecreted
Domains and Gene Ontology detail (23)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2

Gene Ontology

  • Cexternal side of plasma membrane
  • Cextracellular exosome
  • Cextracellular space
  • CFc-gamma receptor III complex
  • Cplasma membrane
  • FIgG binding
  • FIgG receptor activity
  • Fimmune receptor activity
  • Flow-affinity IgG receptor activity
  • Pantibody-dependent cellular cytotoxicity
  • Pcalcium-mediated signaling
  • Pcell surface receptor signaling pathway

254 aa · 29 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalUniProtImmune signallingGO
View supporting evidence

Cell proliferation & survival

  • ·Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activat…

Immune signalling

  • ·antibody-dependent cellular cytotoxicity
  • ·immune response
View underlying pathways (7)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

FCER1GCD247CD19NCAM1TNFRSF8TYROBPFCGR1ASYKNCR1FCGR3BFCGR3A

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

bemarituzumab
Narrow target profilePhase 3Binding agent

Low affinity immunoglobulin gamma Fc region receptor III-A binding agent

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene FCGR3A

Gene-level evidence surfaced through the gene FCGR3Athat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity
0.65Moderately supported

Genetic literature evidence dominant · Open Targets 0.69

Takayasu arteritis
0.43Limited support

Genetic evidence dominant · Open Targets 0.26

Stomach Neoplasms
0.43Limited support

Clinical evidence dominant · Open Targets 0.34

Arthritis, Rheumatoid
0.39Limited support

Genetic evidence dominant · Open Targets 0.21

Leishmaniasis, Cutaneous
0.38Preliminary

Pathway evidence dominant · Open Targets 0.58 · no direct causal or clinical evidence

View evidence synthesis (5)
Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicityModerately supported
0.65
agreement 0.500.81
Genetic literature100%Geneticdup

Open Targets aggregate 0.69 · 1 independent evidence family · 1 not counted as duplicate

Takayasu arteritisLimited support
0.43
agreement 0.290.57
Genetic97%Literature3%

Open Targets aggregate 0.26 · 2 independent evidence families

Stomach NeoplasmsLimited support
0.43
agreement 0.270.58
Clinical96%Literature4%

Open Targets aggregate 0.34 · 2 independent evidence families

Arthritis, RheumatoidLimited support
0.39
agreement 0.250.53
Genetic67%Literature33%

Open Targets aggregate 0.21 · 2 independent evidence families

Leishmaniasis, CutaneousPreliminary
0.38
agreement 0.150.61
Pathway100%

Open Targets aggregate 0.58 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity0.69
Leishmaniasis, Cutaneous0.58
Stomach Neoplasms0.34
Takayasu arteritis0.26
Arthritis, Rheumatoid0.21
Carcinoma, Squamous Cell0.19
Neoplasms0.13
immunoglobulin G4-related sclerosing disease0.12

Drug development

2 compounds recorded · 2 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (2)
BEMARITUZUMABPhase 3
IMGATUZUMABPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

AntibodiesStrong

Advanced Clinical and UniProt loc high conf support this modality.

Protein degradersEmerging

Feasibility evidence (half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandAB · Advanced ClinicalAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

11

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (7)

COMPLETED · via bemarituzumab · NCT02213289

ClinicalTrials.gov via the drug-target graph.

What's happening now

2

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-07-29

    A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).

    Status changed to Terminated · ClinicalTrials.gov · via bemarituzumab

  2. New publication2024-02-03
    Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024 · 50 citations · Europe PMC · via bemarituzumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.